Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis
Human body cells are stem cell (SC) derivatives originating from bone marrow. Their special characteristics include their capacity to support the formation and self-repair of the cells. Cancer cells multiply uncontrollably and invade healthy tissues, making stem cell transplants a viable option for...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/24/2855 |
| _version_ | 1827575326503337984 |
|---|---|
| author | Sulaiman Mohammed Alnasser Khalid Saad Alharbi Ali F. Almutairy Sulaiman Mohammed Almutairi Abdulmalik Mohammed Alolayan |
| author_facet | Sulaiman Mohammed Alnasser Khalid Saad Alharbi Ali F. Almutairy Sulaiman Mohammed Almutairi Abdulmalik Mohammed Alolayan |
| author_sort | Sulaiman Mohammed Alnasser |
| collection | DOAJ |
| description | Human body cells are stem cell (SC) derivatives originating from bone marrow. Their special characteristics include their capacity to support the formation and self-repair of the cells. Cancer cells multiply uncontrollably and invade healthy tissues, making stem cell transplants a viable option for cancer patients undergoing high-dose chemotherapy (HDC). When chemotherapy is used at very high doses to eradicate all cancer cells from aggressive tumors, blood-forming cells and leukocytes are either completely or partially destroyed. Autologous stem cell transplantation (ASCT) is necessary for patients in those circumstances. The patients who undergo autologous transplants receive their own stem cells (SCs). The transplanted stem cells first come into contact with the bone marrow and then undergo engraftment, before differentiating into blood cells. ASCT is one of the most significant and innovative strategies for treating diseases. Here we focus on the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, and AL amyloidosis, using ASCT. This review provides a comprehensive picture of the effectiveness and the safety of ASCT as a therapeutic approach for these diseases, based on the currently available evidence. |
| first_indexed | 2024-03-08T20:54:43Z |
| format | Article |
| id | doaj.art-6e46e7bbc4a04c17a811bc1760be5c1a |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-08T20:54:43Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-6e46e7bbc4a04c17a811bc1760be5c1a2023-12-22T13:59:47ZengMDPI AGCells2073-44092023-12-011224285510.3390/cells12242855Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL AmyloidosisSulaiman Mohammed Alnasser0Khalid Saad Alharbi1Ali F. Almutairy2Sulaiman Mohammed Almutairi3Abdulmalik Mohammed Alolayan4Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi ArabiaDepartment of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi ArabiaDepartment of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi ArabiaUnaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi ArabiaUnaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi ArabiaHuman body cells are stem cell (SC) derivatives originating from bone marrow. Their special characteristics include their capacity to support the formation and self-repair of the cells. Cancer cells multiply uncontrollably and invade healthy tissues, making stem cell transplants a viable option for cancer patients undergoing high-dose chemotherapy (HDC). When chemotherapy is used at very high doses to eradicate all cancer cells from aggressive tumors, blood-forming cells and leukocytes are either completely or partially destroyed. Autologous stem cell transplantation (ASCT) is necessary for patients in those circumstances. The patients who undergo autologous transplants receive their own stem cells (SCs). The transplanted stem cells first come into contact with the bone marrow and then undergo engraftment, before differentiating into blood cells. ASCT is one of the most significant and innovative strategies for treating diseases. Here we focus on the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, and AL amyloidosis, using ASCT. This review provides a comprehensive picture of the effectiveness and the safety of ASCT as a therapeutic approach for these diseases, based on the currently available evidence.https://www.mdpi.com/2073-4409/12/24/2855autologous stem cell transplantationcancersoncologyHodgkin’s lymphomanon-Hodgkin’s lymphomamultiple myeloma |
| spellingShingle | Sulaiman Mohammed Alnasser Khalid Saad Alharbi Ali F. Almutairy Sulaiman Mohammed Almutairi Abdulmalik Mohammed Alolayan Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis Cells autologous stem cell transplantation cancers oncology Hodgkin’s lymphoma non-Hodgkin’s lymphoma multiple myeloma |
| title | Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis |
| title_full | Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis |
| title_fullStr | Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis |
| title_full_unstemmed | Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis |
| title_short | Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis |
| title_sort | autologous stem cell transplant in hodgkin s and non hodgkin s lymphoma multiple myeloma and al amyloidosis |
| topic | autologous stem cell transplantation cancers oncology Hodgkin’s lymphoma non-Hodgkin’s lymphoma multiple myeloma |
| url | https://www.mdpi.com/2073-4409/12/24/2855 |
| work_keys_str_mv | AT sulaimanmohammedalnasser autologousstemcelltransplantinhodgkinsandnonhodgkinslymphomamultiplemyelomaandalamyloidosis AT khalidsaadalharbi autologousstemcelltransplantinhodgkinsandnonhodgkinslymphomamultiplemyelomaandalamyloidosis AT alifalmutairy autologousstemcelltransplantinhodgkinsandnonhodgkinslymphomamultiplemyelomaandalamyloidosis AT sulaimanmohammedalmutairi autologousstemcelltransplantinhodgkinsandnonhodgkinslymphomamultiplemyelomaandalamyloidosis AT abdulmalikmohammedalolayan autologousstemcelltransplantinhodgkinsandnonhodgkinslymphomamultiplemyelomaandalamyloidosis |